Has significantly reduced side effects of the current diabetes drugs on the 
market 

Maximize effectiveness by reducing drug and insulin resistance from long-term 
use

Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd. (KOSDAQ:89140), 
said it has secured a 50% stake in RosVivo Therapeutics Inc., a U.S. new drug 
developer, as its first investment destination. RosVivo recently developed 
RSVI-301, a new drug pipeline that utilizes miRNA (MicroRNA), which is expected 
to be the next-generation drug, following mRNA (Messenger RNA), which has 
attracted attention as a Covid-19 vaccine. Unlike rare diseases or cancer, 
targeting chronic disease "diabetes," seems to have positively affected Nexturn 
Bio's investment. 

According to data released by the WHO in April this year, the number of 
diabetes patients worldwide is about 420 million, which has maintained a high 
prevalence rate until recently. The figure of the patients proves that diabetes 
drugs currently developed up to the fourth generation are not as effective as 
expected. In fact, Liraglutide, which are known to be the most effective 
component of diabetes drugs ever approved by the FDA, have also reported 
vomiting, diarrhea, constipation and indigestion as side effects from the 
clinical stages. The side effect reduction of RSVI-301 is more noticeable in 
the table below, compiled according to the research paper provided by RosVivo. 
(figure 1). 

Furthermore, it has been observed that RSVI-301 reduces insulin resistance by 
normal levels during repeated drug infusions (figure 2). With the result of 
being completely opposite to the existing diabetes drugs, the possibility of 
overcoming insulin resistance raises RSVI-301 expectations in the related 
industry. The low side effects and the long-term lasting effects of RSVI-301 
are expected to play a major competitive role in the future diabetes market in 
regard to patient convenience. An official from Nexturn Bio Inc. added, "We 
will continue to provide generous support for RosVivo's development of new 
drugs as well as to cure diabetes together." 

SOURCE NEXTURN Bio Inc.

Image Attachments Links:

   Link: https://iop.asianetnews.net/view-attachment?attach-id=390537

   Caption: Rosvivo’s new miRNA treatment RSV1-301 vs. diabetes drug on the 
market

   Link: https://iop.asianetnews.net/view-attachment?attach-id=390647

   Caption: Insulin resistance and secretion changes after injection of the new 
drug miRNA